Lactobacillus rhamnosus GG (LGG®) probiotic: what do we know about its efficiency and safety?
Abstract
Current data on the role of probiotic strain Lactobacillus rhamnosus LGG® in pediatric practice are presented. LGG® strain is widely used both as a component of infant formulas and of medical preparations. Lactobacillus LGG® has a high degree of resistance to gastric acid and to bile salts, due to pili, the adhesion to intestinal epithelial cells is realized. LGG® is characterized by an active persistance of colonization of human colonic mucosa. Besides the inhibition of pathogens they participate in intestinal microbiota modulation, support reduction of risk of allergic diseases and provide formation of immunological tolerance.
About the Authors
S. G. Gribakin
ФГБОУ ДПО РМАНПО МЗ РФ
Russian Federation
Russian Federation
A. G. Timofeeva
ФГАУ НМИЦ здоровья детей МЗ РФ
Russian Federation
Russian Federation
O. A. Bokovskaya
АО «ИНФАПРИМ»
Russian Federation
Russian Federation
References
1. Gorbach S. L. Probiotics and gastrointestinal health // Am. J. Gastroenterol. 2000. Vol. I, p. 2-4.
2. Goldin B. R., Gorbach S. L., Saxelin M., Barakat S., Gualtieri L., Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract // Dig Dis Sci. 1992, vol. 37 p. 121-128.
3. Корниенко Е. А., Мазанкова Л. Н., Горелов А. В., Ших Е. В., Намазова-Баранова Л. С., Беляева И. А. Применение пробиотиков в педиатрической практике: анализ лечебного и профилактического действия с позиций доказательной медицины // Лечащий Врач. 2015, № 9, 7-13.
4. Сафонова М. А., Кузнецов О. Ю. Пробиотические препараты для коррекции микроэкологических нарушений кишечника // Вестник Ивановской медицинской академии. 2012, т. 17, № 1, 49-54.
5. Doron S., Snyderman D. R. Risk and safety of probiotics // CID. 2015, vol. 60 (suppl. 2), S129-S134.
6. Mandal H., Jariwala R., Bagchi T. Isolation and characterization of lactobacilli from human feces and indigenous fermented foods for their potential application as probiotics // Can J Microbiol. 2016, vol. 62 (4), p. 349-359.
7. Salminen S., Gueimonde M. Gut mivrobiota in infants between 5 and 24 months of age // Nestle Nutr Workshop, Ser Pediatr Progr. 2005, vol. 56, p. 43-51.
8. Binns N. Probiotics, prebiotics and the gut microbiota / ILSI Europe, Concise Monograph Series, 2013.
9. Gawronska A., Dziechciarz P., Horvath A. et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children // Aliment Pharmacol Ther. 2007; vol. 25, p. 177-184.
10. Francavilla R., Muniella V., Magista A. M. Randonised placebo controlled study of Lactobacillus GG in infants with abdominal pain // Akiment Pharmacol Ther. 2007, vol. 25, p. 177-184.
11. Partty A., Kalliomaki M., Endo A. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy // PloS One. 2012, vol. 7 (3), e32495.
12. Суржик А. В. Влияние пробиотической культуры Lactobacillus rhamnosus GG на иммунный ответ организма // Вопр. совр. педиатрии. 2009, т. 8, № 23, с. 54-58.
13. Hatakka K., Savilahti E., Ponka A. Effectof long term consumption of probiotic milk on infection of children attending day care centers: double blind randomized study // BMJ. 2001, vol. 322, p. 1327-1329.
14. Hojsak I., Abdovic S., Szajewska H., Milosevic M., Krznaric Z., Kolacek S. Lactobacillus GG in the Prevention of Nosocomial Gastrointestinal and Respiratory Tract Infections // Pediatrics. 2010, vol. 125: E1171-E1177.
15. Isolauri E., Kalliomaki M., Laitinen K., Salminen S. Modulation of development of intestinal barrier function and microbiota: a new aim of treatment of allergic diseases // Curr Pharm Des. 2008; 14: 1368-1375.
16. Боровик Т. Э., Макарова С. Г., Яцык Г. В., Степанова Т. Н., Грибакин С. Г. Роль нарушений барьерной функции кишечника в развитии пищевой аллергии у детей // Вопр. совр. педиатрии. 2013, т. 12, № 2, с. 12-19.
17. Kalliomaki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial // Lancet. 2001, vol. 357: p. 1076-1079.
18. Kalliomaki M., Salminen S., Poussa T., Arvilommi H., Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial // Lancet. 2003, vol. 361: p. 1869-1871.
19. Kalliomaki M., Salminen S., Poussa T., Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo- controlled trial // J Allergy Clin Immunol. 2007, vol. 119: p. 1019-1021.
20. Berni Canani R., Nocerino R., Terrin G., Frediani T., Lucarelli S., Cosenza L., Passariello A., Leone L., Granata V., Di Costanzo M. Formula selection for management of children with cow’s milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study // J Pediatr. 2013, vol. 163: p. 771-777.
21. Scalabrin D. M., Harris C., Johnston W. H. Long-term safety assessment in children who received hydrolyzed protein formula with Lactobacillus rhamnosus GG: a 5-year follow-up // Eur J Pediatr. 2017, vol. 176, p. 217-224.
22. Lundelin K., Poussa T., Salminen S. Long-term safety and efficacy of perinatal probiotic intervention // Pediatr. Allergy Immunol. 2017, vol. 28, p. 170-175.
Review
For citations:
Gribakin S.G., Timofeeva A.G., Bokovskaya O.A. Lactobacillus rhamnosus GG (LGG®) probiotic: what do we know about its efficiency and safety? Lechaschi Vrach. 2019;(4):92. (In Russ.)
Views:
316
JATS XML
Email this article 
